AGER and amyloidosis: DSS reduced the deposition of amyloidosis and amyloid β1-42 in the brains of APP/PS1 mice, downregulated the receptor for advanced glycation end products (RAGE), and upregulated the level of low-density lipoprotein receptor-related protein-1.